Levin Capital Strategies’s Ocular Therapeutix OCUL Stock Holding History

Levin Capital Strategies’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$98.2K	Buy	+10,000	New	+$90.6K	0.01%	254
2025 Q4	–	Sell	-15,000	Closed	-$175K	–	247
2025 Q3	$175K	Buy	+15,000	New	+$179K	0.02%	199
2023 Q4	–	Sell	-22,500	Closed	-$70.7K	–	290
2023 Q3	$70.7K	Sell	22,500 -10,000	-31%	-$40.9K	0.01%	249
2023 Q2	$168K	Sell	32,500 -175,124	-84%	-$1.04M	0.02%	219
2023 Q1	$1.09M	Sell	207,624 -63,068	-23%	-$299K	0.14%	78
2022 Q4	$761K	Buy	270,692 +14,848	+6%	+$49.2K	0.1%	95
2022 Q3	$1.06M	Buy	255,844 +123,190	+93%	+$621K	0.14%	79
2022 Q2	$533K	Buy	+132,654	New	+$501K	0.06%	122
2020 Q3	–	Sell	-73,678	Closed	-$614K	–	283
2020 Q2	$614K	Buy	73,678 +43,678	+146%	+$290K	0.08%	95
2020 Q1	$148K	Sell	30,000 -15,000	-33%	-$74.1K	0.02%	141
2019 Q4	$178K	Buy	+45,000	New	+$156K	0.02%	188

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Levin Capital Strategies's OCUL Position: Q2 2026 in Review

Levin Capital Strategies opened a new position in Ocular Therapeutix (OCUL) in Q2 2026: 10,000 shares worth $98.2K. The stake represents 0.01% of the portfolio and ranks #254 among its holdings. This is a return to the name: Levin Capital Strategies previously reported a position in OCUL as recently as Q3 2025.

Levin Capital Strategies first reported a position in OCUL in Q4 2019 and has held it in 11 quarters since. The position peaked at $1.09M in Q1 2023. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Levin Capital Strategies held 10,000 shares of Ocular Therapeutix worth $98.2K as of Q2 2026.
Ocular Therapeutix was a new Levin Capital Strategies position in Q2 2026.
Ocular Therapeutix made up 0.01% of Levin Capital Strategies's portfolio in Q2 2026, its #254 holding.
Levin Capital Strategies first reported a position in Ocular Therapeutix in Q4 2019 and has held it in 11 quarters since.
Levin Capital Strategies's Ocular Therapeutix position peaked at $1.09M in Q1 2023.
263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Levin Capital Strategies's 13F filing for Q2 2026, filed 31 Jul 2026.